

## In this issue:

- Impact of DMTs on COVID-19 risk in pwMS
- Use of DMTs in pregnancy
- Critical spinal cord lesions and secondary progressive motor impairment
- Prediction of on-treatment disability worsening in RRMS
- Functional electrical stimulation for foot drop in pwMS
- Real-world efficacy of natalizumab in patients with RRMS
- Disability outcomes in patients with early cerebellar or brainstem symptoms
- Breastfeeding and MS treatments
- Discontinuing cannabis may improve depression in pwMS
- Defining the course of tumefactive MS

### Abbreviations used in this issue

**ARR** = annualised relapse rate  
**CSF** = cerebrospinal fluid  
**COVID-19** = coronavirus disease 2019  
**CNS** = central nervous system  
**DMT** = disease-modifying therapy  
**EDSS** = Expanded Disability Status Scale  
**HR** = hazard ratio  
**MAGNIMS** = Magnetic Resonance Imaging in MS  
**MRI** = magnetic resonance imaging  
**MS** = multiple sclerosis  
**pwMS** = people with MS  
**RRMS** = relapsing-remitting MS  
**SPMS** = secondary progressive MS

Kindly supported by

**NANZ - Neurological  
Society of New Zealand**



Research Review  
New Zealand is now  
on LinkedIn

[FOLLOW US](#) TO KEEP UP TO DATE

## Welcome to the latest issue of Neurology Research Review, focusing specifically on MS.

In this issue, a systematic review looks at the impact of DMTs on COVID-19 risk in pwMS, an analysis of MSBase Registry data investigates pregnancy-related disease activity in women with MS, and a population-based case-control study finds that critical spinal cord lesions may be important contributors to motor progression in MS. Also in this issue, an analysis of the Tysabri Observational Program reports disability improvement in patients taking natalizumab for RRMS, and a Canadian study finds that stopping cannabinoid medications in pwMS who have depression may in fact improve their mood.

We hope you find the selected studies interesting, and welcome your feedback.

Kind regards,

**Dr Jennifer Pereira**

[jenniferpereira@researchreview.co.nz](mailto:jenniferpereira@researchreview.co.nz)

## COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system

**Authors:** Sharifian-Dorche M et al.

**Summary:** This systematic review investigated the impact of DMTs on COVID-19 risk in patients with demyelinating diseases of the CNS (including MS). A search of PubMed from Jan to Dec 2020 identified 84 articles that evaluated COVID-19 in a total of 2493 patients with MS. Overall, 1.8% of them died. Rituximab had the highest mortality rate of the DMTs (4%). Not many studies reported a link between DMT use and the disease course of COVID-19, but other variables such as age, higher EDSS scores, cardiac comorbidities, and obesity were independent risk factors for severe COVID-19. After infection, an attenuation of immune response was seen in patients taking fingolimod and anti-CD20 monoclonal antibodies.

**Comment:** As the COVID-19 pandemic was unfolding we firstly relied on expert opinion based on scientific principles, then early case series and then larger databases to inform decision making around the initiation and continuation of DMTs for pwMS. This large systematic review supports current practice to not interrupt dosing. As we head into the next phase, assessing the safety and efficacy of the COVID vaccine in pwMS on DMTs, there is no theoretical reason that the vaccines would pose a greater risk to individuals on DMTs but as suggested in this paper, the efficacy may be attenuated for those on ocrelizumab or fingolimod.

**Reference:** *Mult Scler Relat Disord* 2021; published online Jan 29

[Abstract](#)

## Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis

**Authors:** Yeh WZ et al., for the MSBase Study Group

**Summary:** This study analysed data from the MSBase Registry to investigate pregnancy-related disease activity in women with MS. 1998 pregnancies from 1619 women with RRMS or clinically isolated syndrome were included. Overall, ARR decreased during pregnancy, before increasing again postpartum. ARR spiked after delivery in all DMT groups, but breastfeeding women were less likely to relapse (HR 0.61, 95% CI 0.41–0.91;  $p=0.016$ ). 5.6% of pregnancies were followed by disability progression that was predicted by higher relapse activity in pregnancy and postpartum.

**Comment:** This paper helps to inform management strategies for women of childbearing age planning for pregnancy. Pregnancy is “protective” for pwMS but in the treatment era those stopping fingolimod and natalizumab preconception are at risk of a relapse during pregnancy. Those at greatest risk had a preconception EDSS of  $\geq 2$  and a high preconception ARR. Early initiation of treatment postpartum is important – reducing ARR by 89%. This must be done early as the median time of relapse was 34 days postpartum.

**Reference:** *Neurol* 2021; published online Apr 20

[Abstract](#)

## Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS

**Authors:** Sechi E et al.

**Summary:** This population-based case-control study investigated whether critical spinal cord lesions are more common in patients with long-standing SPMS or long-standing RRMS. Brain and spine MRI data for 14 patients with long-standing SPMS were compared with those of 18 patients with long-standing RRMS. Median disease duration (39 vs 34 years) and relapse number (3 vs 4) were similar between groups. Compared with RRMS patients, those with SPMS more commonly had potential critical spinal cord lesions (44% vs 100% of patients, respectively), more spinal cord lesions (median 4 vs 7.5), and more brain infratentorial lesions (median 1 vs 2.5; all  $p < 0.05$ ). Multivariate analysis showed that the presence of potential critical lesions was independently associated with motor progression ( $p = 0.02$ ).

**Comment:** In this study, all SPMS patients had at least 1 focally atrophic lesion in the lateral column of the spinal cord. Early, effective treatment for those with active disease is likely to be the best strategy to prevent the development of these critical lesions. Also in this cohort, 44% of RRMS patients had a similar potentially critical lesion and the authors discuss the potential variation of intralésional and patient factors that determine the clinical course. Perhaps these 44% are all destined to develop SPMS or there may be important modifying factors such as “greater functional neural reserve” – further research is required to understand these factors better.

**Reference:** *Mult Scler* 2021;27(5):667-73

[Abstract](#)

## Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

**Authors:** Kunchok A et al., for the MSBase Study Group

**Summary:** This analysis of MSBase data examined the prognostic value of relapses, MRI activity and the MAGNIMS score for predicting disability worsening during treatment with interferon-beta and 3 other DMTs. 2293 pwMS were included in the analysis. Cox proportional hazards models found that 3 new T2 lesions (HR, 1.60;  $p = 0.028$ ) or 2 relapses (HR, 2.24;  $p = 0.002$ ) in pwMS taking interferon-beta for 12 months were predictive of disability worsening over 4 years. A MAGNIMS score of 2 (1 relapse and  $\geq 3$  T2 lesions, or  $\geq 2$  relapses) was also associated with a greater risk of disability worsening in patients taking interferon-beta (HR, 2.0;  $p = 0.001$ ). Similar associations were seen when the data for interferon-beta were pooled with 3 other DMTs (MAGNIMS score of 2: HR, 1.72;  $p = 0.001$ ).

**Comment:** During a routine follow-up appointment for pwMS on DMTs we focus on the safety, efficacy and tolerability of the current treatment regimen. This piece of research uses MSBase to aid in the identification of those experiencing treatment failure. Most patients are stable but if there is evidence of ongoing clinical and/or radiological disease activity your patient should be switched to a higher efficacy agent to minimise the risk of future disability.

**Reference:** *Mult Scler* 2021;27(5):695-705

[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

## Functional electrical stimulation for foot drop in people with multiple sclerosis

**Authors:** Smith AD et al.

**Summary:** Foot drop is a common cause of mobility impairment in pwMS. This literature review evaluated published evidence of the use of functional electrical stimulation (FES) for the treatment of foot drop in MS. The strengths and weaknesses of FES were discussed, as well as the benefits of using it in combination with physiotherapy.

**Comment:** FES offers an alternative to an orthosis as a management strategy for foot drop complicating MS. It has the added benefit of being an active rather than passive measure. Electrical impulses are delivered to the common peroneal nerve and tibialis anterior. An FES device can be purchased for a cost of approximately \$NZ2500. Patients who can afford to self-fund this and wish to have an assessment to determine if it would be beneficial can be referred to a neurological physiotherapist.

**Reference:** *Mult Scler* 2021;27(5):653-60

[Abstract](#)

## Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

**Authors:** Wiendl H et al., on behalf of the Tysabri Observational Program (TOP) Investigators

**Summary:** This analysis of TOP data investigated real-world disability improvement in RRMS patients treated with natalizumab. Confirmed disability improvement (CDI) was defined as a  $\geq 1.0$  point decrease in EDSS score from baseline. 1278 out of 5384 patients (23.9%) treated with natalizumab had CDI, with approximately half of them having improvements in the first year of treatment. Among patients with CDI, 56.6% had an EDSS decrease of  $\geq 1.5$  points and 34.4% had a decrease of  $\geq 2.0$  points. The cumulative probability of maintaining improvement for 8 years was calculated to be 52.6%.

**Comment:** The main aim of treatment of active MS is to stabilise and prevent future disability. The statistics provided in this paper allow an informed discussion about the potential for improvement. 24% of patients on natalizumab will experience a sustained improvement and this does not necessarily happen in the first year. It is more likely to occur in those with a shorter disease duration – ideally within 1 year after symptom onset. This improvement does translate to a meaningful clinical benefit with a third achieving a drop in their EDSS by  $\geq 2$  points.

**Reference:** *Mult Scler* 2021;27(5):719-28

[Abstract](#)

## Physiotherapy Board of New Zealand


Reading Research Reviews can be included in registered Physiotherapists CPD plan and recorded as part of 100 hours of CPD over a three year period.

Please [CLICK HERE](#) to download CPD Information

Independent commentary by  
**Dr Jennifer Pereira** BHB, MBChB, FRACP, MD



After undergraduate training in medicine at the University of Auckland, Jennifer trained in neurology at Auckland City Hospital. Postgraduate training consisted of an MS research fellowship, with the Therapeutic Immunology Group in the Department of Clinical Neurosciences, University of Cambridge (UK). **For full bio** [CLICK HERE](#)



**Tecfidera**  
(dimethyl fumarate)  
BECAUSE TOMORROW  
MATTERS TODAY

# TECFIDERA GIVES YOUR RRMS PATIENTS FLEXIBILITY IN FAMILY PLANNING<sup>1-3</sup>



## WHY CHOOSE TECFIDERA FOR WOMEN OF CHILDBEARING AGE?



TECFIDERA is the ONLY oral treatment for RRMS with an Australian Pregnancy Category B1<sup>1,4-7\*</sup>



No adverse pregnancy outcomes have emerged in over 9 years of clinical trial and real-world experience<sup>2,3,8</sup>



TECFIDERA can be used until conception<sup>1\*,†</sup>



TECFIDERA gives patients the freedom to choose their preferred contraceptive method, or to not use contraception at all<sup>1</sup>

Data from nonclinical (animal) studies do not suggest that TECFIDERA would be associated with an increased risk of teratogenicity or reduced fertility in either males or females.<sup>1,†</sup>

\*TECFIDERA should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the foetus. No washout period required before conception. TECFIDERA is not contraindicated in pregnancy.<sup>1</sup> †TECFIDERA has a terminal half-life of ~1 hour, and no measurable metabolite is present at 24h in the majority of individuals.<sup>1</sup> †Animal data does not necessarily predict human clinical effect.



RRMS=relapsing-remitting multiple sclerosis.

**Reference:** 1. Tecfidera (dimethyl fumarate) Data Sheet, 5 March 2020. 2. Gold R *et al.* *Neurol Ther* 2015;4:93-104. 3. Hellwig K *et al.* Poster presented at ACTRIMS-ECTRIMS: September 11-13 2020. Virtual conference. 4. Gilenya (fingolimod) Data Sheet, 20 July 2020. 5. Aubagio (terifunomide) Data Sheet, 18 August 2020 / Aubagio (terifunomide) Product Information, 17 September 2020. 6. Fampyra (fampridine) Data Sheet, 31 January 2020. 7. Mavenclad (cladribine) Data Sheet, 11 May 2020 / Mavenclad (cladribine) Product Information, 15 January 2021. 8. Gold R *et al.* *Ther Adv Neurol Disord* 2020;13:1-17. 9. Desai A *et al.* *Eur J Pharm Med Res* 2016;3(5):197-205.

Before prescribing TECFIDERA please review the Data Sheet available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

**TECFIDERA** (dimethyl fumarate [DMF]) 120 mg and 240 mg modified release capsules **INDICATIONS:** indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability. **CONTRAINDICATIONS:** known hypersensitivity to DMF or any excipients in this product. **PRECAUTIONS:** Decreases in lymphocyte counts observed in patients treated in clinical trials were not associated with increased frequencies of infections. Due to the risk of serious, possibly fatal infection, patients who develop lymphopenia as a result of treatment, require close monitoring. Instruct patients to report symptoms of infection to their physician. For patients with signs and symptoms of serious infections, interrupting treatment should be considered until the infection(s) resolves. TECFIDERA may decrease lymphocyte counts. Prior to initiating treatment, a recent complete blood count (CBC) including lymphocytes (i.e. within 6 months) is recommended. A CBC, including lymphocytes, is also recommended after 6 months of treatment and every 6 to 12 months thereafter, and as clinically indicated. Consider interruption in patients with lymphocyte counts <0.5 x 10<sup>9</sup>/L persisting for more than 6 months. Lymphocyte counts should be followed until recovery. Assess benefit/risk in patients that experience moderate lymphopenia ≥6 months. Use caution in patients with pre-existing low lymphocyte counts. Progressive multifocal leukoencephalopathy (PML) has occurred in the setting of lymphopenia (<0.91 x 10<sup>9</sup>/L) in MS patients treated with Tecfidera. At the first sign or symptom suggestive of PML, withhold treatment and perform an appropriate diagnostic evaluation. Cases of anaphylaxis have also been reported. Patients should be instructed to discontinue and seek immediate medical care if they experience signs or symptoms of anaphylaxis and treatment should not be restarted. Serious cases of herpes zoster have occurred with TECFIDERA. Consider withholding TECFIDERA treatment in patients with serious infections until the infection has resolved. Patients taking TECFIDERA may receive non-live vaccines. Live vaccines are not recommended during treatment. Prior to initiating treatment, urinalysis should be available (within 6 months prior to starting therapy). During treatment, urinalysis is recommended annually and as clinically indicated. Use caution in patients who receive chronic medications associated with potential nephrotoxic risk. Pregnancy Category B1. Others: see full PI. **INTERACTIONS WITH OTHER MEDICINES:** TECFIDERA is extensively metabolised by esterases before it reaches the systemic circulation and further metabolism occurs through the TCA cycle, with no involvement of the CYP450 system. Simultaneous use of other fumaric acid derivatives (topical or systemic) should be avoided. **ADVERSE EFFECTS: Very common (>10%):** Flushing, diarrhoea, nausea, abdominal pain, abdominal pain upper. **Common (>1%):** gastroenteritis, lymphopenia, leucopenia, burning sensation, hot flush, vomiting, dyspepsia, gastritis, gastrointestinal disorder, pruritus, rash, erythema, proteinuria, feeling hot, albumin present in urine, aspartate aminotransferase and alanine aminotransferase increased and white blood cell count decreased. **Post-marketing:** PML has occurred in the setting of lymphopenia (<0.91 x 10<sup>9</sup>/L). Liver function abnormalities which resolved upon treatment discontinuation have been reported, LFTs monitoring is recommended as clinically indicated. Herpes zoster infection has been reported. Cases of anaphylaxis have also been reported. **DOSAGE AND ADMINISTRATION:** Starting dose is 120 mg b.i.d orally. After 7 days, increase to the recommended dose of 240 mg b.i.d orally. Do not crush, divide or dissolve the capsules or contents. Temporary dose reduction to 120 mg b.i.d may reduce flushing and GI side effects. Within 1 month, the 240 mg b.i.d dose should be resumed. Take with or without food. For patients who may experience GI or flushing side effects, taking TECFIDERA with food may improve tolerability. Administration of 325 mg non-enteric coated aspirin prior to dosing reduced the occurrence and severity of flushing in a study. **MEDICINES CLASSIFICATION:** Prescription Medicine. TECFIDERA capsules are supplied in blister packs: 14 for 120 mg and 56 for 240 mg. Store below 30°C. Store in original packaging to protect from light. **REVISION DATE - AUS:** February 2020; **NZL:** February 2020.

**NZ Mandatories:** TECFIDERA is a funded medicine – a prescription charge and Special Authority criteria will apply. Before prescribing please refer to the Data Sheet available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz).

© Biogen and Tecfidera are registered trademarks of Biogen MA Inc. Biogen NZ Biopharma Ltd, 188 Quay Street, Auckland. ©2021 Biogen-975653. TAPS No. BG1035. TEC0160. Date of preparation: March 2021.



## Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

**Authors:** Le M et al.

**Summary:** This analysis of MSBase data investigated long-term disability outcomes in patients with early cerebellar or brainstem symptoms. 10,513 patients were included in the analysis; 2723 had early cerebellar symptoms and 3915 had early brainstem symptoms (patients with early pyramidal presentation were used as a comparator group). Andersen-Gill models showed that early cerebellar presentation was associated with greater risk of progression events (HR, 1.37;  $p < 0.001$ ) compared with patients with early pyramidal presentation. In contrast, patients with early brainstem symptoms had a lower risk of progression events (HR, 0.89;  $p = 0.01$ ). Neither presentation was associated with changes in the risk of relapse.

**Comment:** We have 7 different treatments available in NZ for active MS. These have varying efficacy and side-effect profiles. Treating neurologists advise patients on the best option for them based on clinical and prognostic factors. 10% of pwMS present with an early cerebellar relapse and as detailed in this paper are at risk of more significant disability than those with a pyramidal presentation. Consider these individuals for high-efficacy agents – natalizumab and ocrelizumab.

**Reference:** *Mult Scler* 2021;27(5):755-66

[Abstract](#)

## Breastfeeding and treatment of multiple sclerosis

**Authors:** Celius EG

**Summary:** Breastfeeding may not be sufficient to prevent postpartum relapses in women with highly active MS, so the reinitiation of DMTs is usually indicated. Most DMTs are contraindicated in breastfeeding mothers due to known potential effects in the baby, lack of knowledge about transfer to breast milk, or lack of knowledge about possible uptake in the baby. It is unethical to perform clinical trials in pregnant or breastfeeding women, so clinical practice and prescribing information can only be updated through case reports and case series. Recent evidence suggests that the period of stopping breastfeeding after a treatment course of cladribine may possibly be reduced from 7 to 1–2 days after each treatment cycle. Further studies on MS treatments are needed to help guide the increasing number of women with MS who wish to breastfeed their babies.

**Comment:** Pregnancy and breastfeeding must be considered together when discussing DMTs with women of childbearing age. Cladribine is an oral reconstitution therapy not yet funded by PHARMAC. It is administered in treatment courses – 5 days of tablets in week 1 and week 5 of year 1 and repeated in year 2 with efficacy anticipated through until the end of year 4. It is teratogenic and patients should not conceive or father a child for 6 months after a treatment course. According to the [Association of British Neurologists' guidelines](#) published in *Practical Neurology* in 2019, women should not breastfeed during a treatment course and for 7 days after it.

**Reference:** *Mult Scler* 2021;27(5):801-2

[Abstract](#)

[CLICK HERE](#)

to read previous issues of Neurology Research Review

**Independent Content:** The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. **Research Review publications are intended for New Zealand health professionals.**

## Discontinuing cannabis improves depression in people with multiple sclerosis

**Authors:** Feinstein A et al.

**Summary:** This Canadian study investigated whether symptoms of depression change when pwMS discontinue cannabis use. 40 cognitively impaired pwMS who smoked cannabis almost daily were randomised to either a cannabis continuation group or a cannabis withdrawal group and were followed up for 28 days. Depression scores on the Hospital Anxiety and Depression Scale in pwMS who were using cannabis to manage their depression remained unchanged at day 28 in the cannabis continuation group, but improved in the cannabis withdrawal group ( $p = 0.006$ ).

**Comment:** In the midst of a busy MS clinic, ascertaining what patients are taking for symptomatic management is important. Often patients are prescribed multiple centrally acting drugs – these need to be rationalised particularly if the patient has symptoms of fatigue, cognitive disturbance or depression. Patients may not volunteer they are taking tetrahydrocannabinol, cannabidiol, or a combination. This paper indicates that stopping cannabinoid medications in those with depression who have cognitive impairment may in fact improve their mood.

**Reference:** *Mult Scler* 2021;27(4):636-9

[Abstract](#)

## Defining the course of tumefactive multiple sclerosis

**Authors:** Di Gregorio M et al.

**Summary:** This multicentre retrospective study determined the clinical characteristics and prognostic factors of tumefactive multiple sclerosis (TuMS). Demographic, clinical, MRI, and laboratory data were reviewed for 102 patients with TuMS. TuMS affected women more than men (female to male ratio: 2.4), with a young adulthood onset (median age 29.5 years). At onset, 52% of patients had involvement of more than 1 functional system and 24.5% of them had multiple tumefactive demyelinating lesions (TDLs). Over a third (38.7%) of TDLs had an infiltrative MRI pattern, and approximately three-quarters of patients (76.6%) had immunoglobulin G oligoclonal bands (OCBs) in CSF. 25.3% of patients were treated with more than 1 acute-phase treatment, and 46.6% were treated with high-efficacy treatments. After a median follow-up of 2.3 years, median EDSS score was 1.5. Independent risk factors for reaching an EDSS score  $\geq 3$  were higher age at onset, a higher number of TDLs, and the presence of infiltrative TDLs at baseline.

**Comment:** Early diagnosis of TuMS is challenging as over 50% of patients with this condition present with a multifocal presentation and striking MRI changes that differ from typical MS. This retrospective cohort study identifies where there are similarities – these patients are predominantly female with a mean age of onset of 30 years, 77% have OCBs and detailed analysis of the radiological features shows typical MS lesions in the brain and spinal cord in 85% of patients.

**Reference:** *Eur J Neurol* 2021;28(4):1299-1307

[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

RACP MyCPD Program participants can claim one credit per hour (maximum of 60 credits per year) for reading and evaluating Research Reviews.

FOR MORE INFORMATION [CLICK HERE](#)